Verge Analytics
Latest round
- Series B
Last raised
- Feb 2023
Total raised
- $136M
Investors
- 23
About Verge Analytics
, dba Verge Genomics, engages in research on drug development for neurodegenerative disorders using artificial intelligence. The company was co-founded by its CEO, Alice Zhang, and others. In July 2021, Verge Analytics, Inc.93 million post-money. The company’s pipeline includes VRG50635, which is a small-molecule inhibitor of PIKfyve, and it has already entered clinical trials for amyotrophic lateral sclerosis (ALS). This drug was discovered by its proprietary AI platform, converge®. Verge Genomics programs target therapeutic areas where multi-factorial components (genetics, environment, and time) intersect in complex ways to culminate in overt disease, and animal or cell models do not predict human efficacy. In addition, the company is also working on a variety of treatments, including treatments for Parkinson's disease, frontotemporal dementia, and other conditions that lack therapies. The firm’s partners include Alexion, Lilly, the University of Sheffield, and others.
Who invested in Verge Analytics
23 investors across 6 rounds
See all investors in Verge Analytics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Verge Analytics
Who invested in Verge Analytics?
Verge Analytics has 23 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Verge Analytics raised?
Verge Analytics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Verge Analytics last raise money?
Verge Analytics's most recent round on record is a Series B, in Feb 2023.
What does Verge Analytics do?
, dba Verge Genomics, engages in research on drug development for neurodegenerative disorders using artificial intelligence.
Where is Verge Analytics headquartered?
Verge Analytics is headquartered in San Francisco, US.
Which VCs invest in companies like Verge Analytics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Verge Analytics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Verge Analytics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.